An agile pharma startup with a promising molecule in Phase III clinical trials desired to effectively build brand awareness and educate three distinct audiences on the effects of migraines and the treatment options that could potentially mitigate complications for patients with cardiovascular concerns.
Educating each audience based on their needs with respect to migraine diagnosis, treatment options, and research required tailored content curation with experts including neurologists, MDs, a biotech investment analyst, and CoLucid researchers.
Targeted content was distributed via the website, a third party analyst site, and conferences.
